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BACKGROUND: The role of tobacco smoke exposure in the development and persistence of asthma and rhinoconjunctivitis through childhood into ado-
lescence is unclear.
OBJECTIVES:We assessed the associations of parental smoking from fetal life through adolescence with asthma and rhinoconjunctivitis during child-
hood and adolescence.
METHODS: We analyzed data for 10,860 participants of ﬁve European birth cohort studies from the Mechanisms of the Development of Allergy
(MeDALL) consortium. Parental smoking habits and health outcomes (early transient, persistent, and adolescent-onset asthma and rhinoconjunctivitis)
were based on questionnaires covering the period from pregnancy to 14–16 y of age. Data were combined and analyzed using a one-stage and two-
stage individual participant data meta-analysis.
RESULTS: Overall, any maternal smoking during pregnancy tended to be associated with an increased odds of prevalent asthma [adjusted
odds ratio ðaORÞ=1:19 (95% CI: 0.98, 1.43)], but not prevalent rhinoconjunctivitis [aOR=1:05 (95% CI: 0.90, 1.22)], during childhood and adoles-
cence. In analyses with phenotypes related to age of onset and persistence of disease, any maternal smoking during pregnancy was associated with
early transient asthma [aOR=1:79 (95% CI: 1.14, 2.83)]. Maternal smoking of ≥10 cigarettes=day during pregnancy was associated with persistent
asthma [aOR=1:66 (95% CI: 1.29, 2.15)] and persistent rhinoconjunctivitis [aOR=1:55 (95% CI, 1.09, 2.20)]. Tobacco smoke exposure during fetal
life, infancy, childhood, and adolescence was not associated with adolescent-onset asthma or rhinoconjunctivitis.
CONCLUSIONS: Findings from this combined analysis of ﬁve European birth cohorts strengthen evidence linking early exposure to tobacco smoke
with asthma during childhood and adolescence. Children with high early-life exposure were more likely than unexposed children to have early tran-
sient and persistent asthma and persistent rhinoconjunctivitis. https://doi.org/10.1289/EHP2738
Introduction
The prevalence of asthma, rhinoconjunctivitis, and other allergic
diseases has increased markedly in the past decades (Asher et al.
2006; Patil et al. 2015). Globally, the prevalence of maternal
smoking during pregnancy varies from <10% to >30% (Cheraghi
and Salvi 2009). The role of tobacco smoke exposure and other
lifestyle factors in the epidemic remain unclear (Frazer et al.
2016). Prenatal and perinatal events are fundamental in health, de-
velopment of diseases, and aging (Bousquet et al. 2015). In high-
income countries, the number of pregnant women who smoke is
waning, but in low-income countries, this number is on the rise
(Murin et al. 2011). Neonates and children have little control over
their environment and are vulnerable to the harmful eﬀects of
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tobacco smoke. Exposure early in life, starting from exposure to
maternal smoking during pregnancy, often continues into early
childhood (Murin et al. 2011). Maternal smoking during pregnancy
and secondhand tobacco smoke (SHS) exposure in infancy have
been associated with an increased risk of developing asthma and
rhinitis in young children, and a dose–response relationship has
been suggested (Burke et al. 2012; Grabenhenrich et al. 2014;
Neuman et al. 2012; Thacher et al. 2014; Vardavas et al. 2016).
However, few prospective studies have investigated these risks
among children >10 y of age (Grabenhenrich et al. 2014), and
even less is known about the association between SHS and other
allergic diseases such as rhinoconjunctivitis (Civelek et al. 2010;
Thacher et al. 2014). Moreover, it is unclear if tobacco smoke ex-
posure during the fetal period, in infancy, or in childhood inﬂuen-
ces the onset, progression, or persistence of allergic disease up to
adolescence. Asthma and rhinoconjunctivitis are both heterogene-
ous diseases with many phenotypes suggested to have diﬀerent
etiologies (Ballardini et al. 2015; Bousquet et al. 2011). Rhinocon-
junctivitis tends to debut somewhat later than asthma, and it is
unclear if exposure to maternal smoking during pregnancy or SHS
during early life inﬂuences age at onset or the persistence of
asthma or rhinoconjunctivitis up to adolescence. The associations
between tobacco smoke exposure and characterized phenotypes of
asthma and rhinoconjunctivitis, which extend into adolescence,
have yet to be elucidated.
Long-term birth cohort studies are essential to understanding
the life course and childhood predictors of allergy-related diseases
(Bousquet et al. 2013). However, single cohorts are often under-
powered to provide robust eﬀect estimates. Therefore, within the
MeDALL (Mechanisms of the Development of Allergy) project,
we attempted to better understand the complex associations
between tobacco smoke exposure and asthma as well as rhinocon-
junctivitis by pooling ongoing European birth cohorts (Bousquet
et al. 2011, 2016).
As part of MeDALL, our aim was to examine the association
of exposure to parental smoking during fetal life, infancy, child-
hood, and adolescence with the onset, progression, and persist-
ence of asthma and rhinoconjunctivitis during childhood and
adolescence using data from ﬁve ongoing European birth cohorts.
Methods
Study Design and Participants
This study is based on data from ﬁve ongoing European birth
cohorts in three diﬀerent countries participating in MeDALL. Of
the cohorts included, we selected those with a) relevant informa-
tion on maternal smoking during pregnancy or SHS exposure
during the ﬁrst year of life; b) follow-up between 14 and 16 y of
age; and c) suitable outcome assessments from three predeﬁned
age intervals (4–6, 8–10, and 14–16 y).
The following ﬁve cohorts were included: Children, Allergy,
Milieu, Stockholm, Epidemiology (BAMSE) (single-center, Sweden)
(Wickman et al. 2002), German Infant Nutritional Intervention
(GINIplus) (multicenter, Germany) (Berg et al. 2010), Inﬂuences
of Lifestyle-Related Factors on the Immune System and the
Development of Allergies in Childhood (LISAplus) (multicenter,
Germany) (Zutavern et al. 2008),Multicentre Allergy Study (MAS)
(multicenter, Germany) (Bergmann et al. 1994), and Prevention and
Incidence of Asthma and Mite Allergy (PIAMA) (multicenter, the
Netherlands) (Wijga et al. 2014). BAMSE and MAS were per-
formed in metropolitan areas, and GINIplus, LISAplus, and
PIAMA included children from both urban and mixed urban–rural
areas. PIAMA and GINIplus included children from both interven-
tion and observational study arms, whereas all other cohorts were
purely observational. By design, MAS was risk-enriched, meaning
that the cohort purposely includedmore children with higher allergy
risk. Additionally, in GINIplus, LISAplus, and MAS, preterm chil-
dren (<37weeks gestation) were excluded by study design. The
cohorts recruited newborns between 1990 (MAS) and 1999
(LISAplus), with sample sizes varying from 1,314 (MAS) to 5,991
(GINIplus) participants (Table 1). Further details on study design,
recruitment, and data collection for each cohort are provided in the
supplemental material and elsewhere (Berg et al. 2010; Bergmann
et al. 1994; Wickman et al. 2002; Wijga et al. 2014; Zutavern et al.
2008). In all cohorts, the information on participants’ health and ex-
posure used in this analysis was assessed through repeated question-
naires completed by the parents and children (at 14–16 y of age).
Data and variables were harmonized according to predeﬁned expo-
sure and outcome deﬁnitions (Hohmann et al. 2014).
In each cohort, parents or legal guardians gave written informed
consent, and ethical approval was obtained from local review
boards.
Procedures
Maternal smoking during pregnancy was deﬁned as the mother
smoking ≥1 cigarette=day during any trimester of pregnancy.
SHS exposure during infancy was deﬁned as the mother, fa-
ther, and/or other persons in the home smoking at any time during
the infant’s ﬁrst year of life. For GINIplus, only maternal smoking
habits were queried for this time period, and only for participants
of the intervention study arm (see Table S1). In BAMSE, parental
smoking was queried regardless of location, and in the other
cohorts (GINIplus, LISAplus, MAS, and PIAMA), parental smok-
ing in the dwelling was queried.
SHS exposure during childhood and adolescence was deﬁned
as the mother, father, and/or other persons in the home smoking.
This exposure was divided into four time intervals: 1–2, 4–6,
8–10, and 14–16 y of age.
Health outcomes were determined from symptom-based ques-
tionnaires. Available datawere pooled for three age intervals: 4–6 y,
8–10 y, and 14–16 y. These age ranges were chosen to include data
from as many cohorts as possible. Parental responses were used to
assess disease outcomes at 4–6 and 8–10 y of age, and at 14–16 y of
age, a combination of parental and children’s responses (symptom-
related) were incorporated for PIAMA, GINIplus, LISAplus, and
BAMSE; for MAS, only parental responses were used because
children’s answers were unavailable (see Table S2; see Table S3 for
an outline of the follow-ups and corresponding outcome assessment
intervals in the diﬀerent cohorts). In cohorts with multiple follow-
ups for a speciﬁc age period, the age with the most complete infor-
mationwas used.
Asthma was deﬁned as fulﬁlling at least two of the following
three criteria: a) doctor-diagnosed asthma ever; b) asthma medi-
cation in the past 12 mo; and c) wheezing in the past 12 mo (see
Table S2) (Gehring et al. 2015).
Rhinoconjunctivitis was deﬁned as positive if the following
criteria were fulﬁlled based on reports for the previous 12 mo: a)
problems with sneezing, or a runny, or blocked nose when the
child did not have a cold or ﬂu; and b) nose problem accompa-
nied by itchy-watery eyes (see Table S2) (Gehring et al. 2015).
The deﬁnitions of asthma and rhinoconjunctivitis were agreed
upon by a panel of experts within the MeDALL collaboration
(Gehring et al. 2015).
We categorized asthma and rhinoconjunctivitis into three dis-
tinct phenotypes: early transient, persistent, and adolescent-onset
disease. Early transient disease was deﬁned as having the disease
only during the 4–6 y age interval, but not thereafter (age inter-
vals 8–10 and 14–16 y). Persistent disease was deﬁned as having
the disease of interest at the ﬁrst age interval (4–6 y) and still
having the disease at the latest age interval (14–16 y). Finally, the
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adolescent-onset phenotype was deﬁned as being disease-free at
the ﬁrst two age intervals (4–6 y and 8–10 y) and only having the
disease at the latest age interval (14–16 y).
Potential confounders and modiﬁers of the associations of
asthma and rhinoconjunctivitis with tobacco smoke exposure were
considered. Based on a priori knowledge, we adjusted all models
for child’s sex (male, female); parental allergic history (any mater-
nal or paternal history of asthma or hay fever, yes or no); parental
education level, based on the highest level of education for either
parent (low: primary school, lower vocational, or lower secondary
education; intermediate: intermediate vocational or intermediate/
higher secondary education; high: higher vocational education or
university degree); older siblings (≥1 older sibling at birth, yes or no);
study center for multicenter studies (GINIplus: Munich, Bavaria,
Wesel, or North–Rhine–Westphalia; LISAplus: Munich, Leipzig,
Wesel, or Bad Honnef; and PIAMA: North—Groningen, Friesland,
Drenthe; Central—Utrecht, Gelderland; West—Rotterdam and
surrounding municipalities), and intervention versus observational
study arms (for GINIplus and PIAMA) (Filipiak et al. 2007;
Gehring et al. 2012). We also considered additional covariates,
including cohort, birth weight (g), gestational age at birth (wk),
breastfeeding (exclusive breastfeeding for ≥4 months, or any
breastfeeding for PIAMAparticipants, yes or no),mold or dampness
in the dwelling (signs ofmold or dampness in the home at 0, 1, or 2 y
of age, yes or no), and day-care attendance (any nursery or day care
with other children at 0, 1, or 2 y of age, yes or no). Final models
included the a priori covariates plus breastfeeding and early day-
care attendance, which were selected based on a >5% change in the
odds ratio (OR) with adjustment. In addition, some models of
maternal smoking during pregnancy were adjusted for SHS
throughout childhood (exposure to SHS at any interval between 1
and 2, 4 and 6, 8 and 10, or 14 and 16 y of age), and some models
of SHS during childhood were adjusted for maternal smoking
during pregnancy.
Table 1. Participant characteristics from five European birth cohorts.
Characteristic BAMSE GINIplus LISAplus MAS PIAMA
Country Sweden Germany Germany Germany The Netherlands
Years of recruitment 1994–1996 1995–1998 1997–1999 1990 1996–1997
Number of children at recruitment 4,089 5,991 3,094 1,314 3,963
Number of children included in final study population, n (%) 3,112 (76.1) 2,956 (49.3) 1,456 (47.1) 560 (42.6) 2,519 (63.6)
Number of children with complete information on all selected covariatesa, n (%) 2,928 (71.6) 2,254 (37.6) 733 (23.7) 427 (32.5) 2,423 (61.1)
Maternal smoking during pregnancy, n (%)
Yes 379 (12.2) 352 (12.0) 183 (13.0) 106 (20.1) 362 (14.5)
No 2,732 (87.8) 2,589 (88.0) 1,229 (87.0) 421 (79.9) 2,140 (85.5)
Missing (n) 1 15 44 33 17
SHS during infancy, n (%)
Yes 631 (20.4) 289 (17.2) 215 (15.6) 224 (42.9) 536 (21.4)
No 2,463 (79.6) 1,396 (82.8) 1,161 (84.4) 298 (57.1) 1974 (78.6)
Missing (n) 18 1,271 80 38 9
Male sex, n (%)
Male 1,530 (49.2) 1,468 (49.7) 744 (51.1) 292 (52.1) 1,267 (50.3)
Female 1,582 (50.8) 1,488 (50.3) 712 (48.9) 268 (47.9) 1,252 (49.7)
Missing (n) 0 0 0 0 0
Mean birth weight (g), mean± SD 3,530± 561 3,466± 464 3,483± 448 3,398± 462 3,531± 532
Missing (n) 29 96 0 3 8
Mean gestation age (wk), mean±SD 39:8± 2:0 39:8± 1:5 39:9± 1:2 40:0± 1:5 39:9± 1:6
Missing (n) 0 366 24 13 5
Parental education, n (%)
Low 514 (16.5) 231 (8.2) 49 (3.4) 38 (7.5) 263 (10.5)
Medium 884 (28.4) 793 (28.1) 352 (24.4) 174 (34.7) 866 (34.5)
High 1,710 (55.1) 1,802 (63.7) 1,044 (72.2) 290 (57.8) 1,384 (55.0)
Missing (n) 4 130 11 58 6
Parental allergyb, n (%)
Yes 944 (30.6) 1,303 (46.2) 713 (52.3) 270 (50.3) 1,064 (42.7)
No 2,138 (69.4) 1,520 (53.8) 651 (47.7) 267 (49.7) 1,427 (57.3)
Missing (n) 30 133 92 23 28
Older siblings, n (%)
Yes 1,472 (47.3) 1469 (50.3) 652 (44.8) 219 (39.1) 1234 (49.0)
No 1640 (52.7) 1450 (49.7) 803 (55.2) 341 (60.9) 1285 (51.0)
Missing (n) 0 37 1 0 0
Breastfeeding, n (%)
≥4mo 2442 (80.3) 2031 (70.9) 1138 (82.7) 338 (60.4) 990 (39.6)
<4mo 600 (19.7) 835 (29.1) 238 (17.3) 222 (39.6) 1508 (60.4)
Missing (n) 70 90 80 0 21
Early mold or dampness in dwelling (0–2 y), n (%)
Yes 785 (25.3) 447 (26.1) 559 (39.0) 74 (14.2) 1049 (45.8)
No 2319 (74.7) 1264 (73.9) 875 (61.0) 444 (85.8) 1242 (54.2)
Missing (n) 8 17 22 42 228
Early day care (0–2 y), n (%)
Yes 2548 (84.3) 126 (4.7) 384 (44.6) 145 (29.0) 1,472 (59.2)
No 476 (15.7) 2,586 (95.3) 478 (55.4) 355 (71.0) 1,013 (40.8)
Missing (n) 88 244 594 60 34
Note: Based on children with information about smoke exposure during pregnancy or infancy and at least one health outcome at 14–16 y of age. BAMSE, Children, Allergy, Milieu,
Stockholm, Epidemiology; GINIplus, German Infant Nutritional Intervention; LISAplus, Influences of Lifestyle-Related Factors on the Immune System and the Development of
Allergies in Childhood; MAS, Multicentre Allergy Study; PIAMA, Prevention and Incidence of Asthma and Mite Allergy; SD, standard deviation; SHS, secondhand smoke.
aParticipants in the final study population with complete information on the following covariates: maternal smoking during pregnancy, SHS exposure during infancy, sex, birth weight,
gestational age, parental education, parental allergy, older siblings, breastfeeding, early mold or dampness in dwelling, and early day-care attendance.
bMother and/or father with asthma and/or hay fever.
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Statistical analysis
Data were combined and analyzed using a one-stage and two-stage
individual participant data meta-analysis (IPD-MA) (Debray et al.
2013). In these analyses, the overall associations of maternal
smoking during pregnancy and SHS during infancy with asthma
and rhinoconjunctivitis prevalence until 16 y of age were assessed
in each cohort separately using generalized estimating equation
(GEE) models, taking into account correlation between repeated
observations within subjects. Adjusted cohort-speciﬁc odds ratios
(ORs) and 95% conﬁdence intervals (CIs) were then combined
using inverse variance weighted random eﬀects models, taking
into account possible nonrandom variability within and between
cohorts. Forest plots were produced with sizes of squares repre-
senting the weights of the individual cohort estimates. The I2 sta-
tistic was used to evaluate heterogeneity between the cohorts
(Higgins and Thompson 2002).
Because we had access to primary data and little heterogene-
ity of associations was observed between the cohorts, subsequent
analyses were conducted using a one-stage IPD-MA model with
indicator variables for cohort/study center, which provided addi-
tional power to assess asthma and rhinoconjunctivitis phenotypes.
Multinomial logistic regression was used to examine associations
between exposure to maternal smoking during pregnancy (yes/no
and three categories as described above) and early transient, per-
sistent, and adolescent-onset phenotypes, adjusting for the same
confounders as in cohort-speciﬁc analyses. To assess dose–
response relationships between the number of cigarettes smoked
and health outcomes, the number of cigarettes smoked during
pregnancy (mother) was categorized as follows: a) no smoking
during pregnancy (reference category); b) 1–9 cigarettes/day; and
c) ≥10 cigarettes=day during any trimester. Potential eﬀect modi-
ﬁcation by parental allergy and sex were tested using stratiﬁed
and interaction models. We tested for multiplicative interaction
by including product terms for tobacco smoke exposures and sex
or parental allergy in multivariable regression analyses. Because
asthma and rhinoconjunctivitis often coexist, we also examined
the association of tobacco smoke exposure with asthma only, rhi-
noconjunctivitis only, and concurrent asthma and rhinoconjuncti-
vitis. Each analysis was limited to participants with complete
data on the exposure, outcome, and covariates included in that
analysis.
All statistical analyses were performed with STATA statisti-
cal software (release 12; StataCorp LLC).
Results
Study Participants
The ﬁnal study population consisted of 10,603 participants
for whom information was available on tobacco smoke exposure
during pregnancy, infancy, or both, and on at least one health
outcome in the age interval 14–16 y (57% of the 18,454 children
at recruitment). The distributions of environmental exposures
and potential confounders in the study population are given in
Table 1 [see Table S4 for the distributions for the entire (baseline)
cohort].
The prevalence of maternal smoking during pregnancy ranged
from 12–20%, and SHS exposure during infancy ranged from
16–43% (see Figure S1). The prevalence of parental smoking was
relatively similar across the cohorts, with the exception of the
MAS cohort, which had the highest prevalence.
The prevalence of asthma varied across cohorts (Figure 1). At
all ages, the prevalence was highest in BAMSE. In GINIplus,
LISAplus, and MAS the prevalence nearly doubled from preschool
age to primary school age. The prevalence of rhinoconjunctivitis
increased with age in all cohorts, and higher prevalences were
observed in GINIplus, LISAplus, and MAS than in BAMSE and
PIAMA (Figure 1).
The prevalences of diﬀerent asthma phenotypes were compa-
rable (3.1% for early transient, 4.0% for persistent, and 4.3% for
adolescent-onset asthma), whereas the prevalence of rhinocon-
junctivitis was highest for adolescent-onset (12.2%) compared
with early transient (1.6%) and persistent rhinoconjunctivitis
(3.5%) (see Figure S2).
Tobacco Smoke Exposure and Prevalence of Asthma and
Rhinoconjunctivitis
Overall, after adjustment for confounders, we observed increased
but not statistically signiﬁcant odds of prevalent asthma up
Figure 1. Prevalence of asthma and rhinoconjunctivitis in ﬁve European birth cohorts. Note: BAMSE, Children, Allergy, Milieu, Stockholm, Epidemiology;
GINIplus, German Infant Nutritional Intervention; LISAplus, Inﬂuences of Lifestyle-Related Factors on the Immune System and the Development of Allergies
in Childhood; MAS, Multicentre Allergy Study; PIAMA, Prevention and Incidence of Asthma and Mite Allergy.
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to 14–16 y of age with any maternal smoking during pregnancy
[OR=1:19 (95% CI: 0.98, 1.43)] and SHS exposure during
infancy [OR=1:15 (95% CI: 1.00, 1.31)] (Figure 2). Heterogen-
eity of cohort-speciﬁc estimates was low for both maternal smok-
ing during pregnancy and SHS during infancy (I2 = 8:1% and
I2 = 0%, respectively).
Neither maternal smoking during pregnancy nor SHS exposure
during infancy was associated with prevalence of rhinoconjunctivi-
tis up to 14–16 y of age, OR=1:05 (95% CI: 0.90, 1.22) and
OR=1:05 (95% CI: 0.92, 1.19), respectively (Figure 3). There was
no signiﬁcant heterogeneity between the studies (I2 = 0% and
I2 = 0%, respectively).
Figure 2. Associations between maternal smoking during pregnancy (N =9,052) or any secondhand smoke (SHS) during infancy (N =7,970) and preva-
lence of asthma up to 14–16 y of age in ﬁve European birth cohorts. Cohort-speciﬁc odds ratios (ORs) and 95% conﬁdence intervals (CIs) were obtained
by generalized estimating equation models. Adjusted for sex, parental education level, parental allergy, older siblings, breastfeeding, study center, interven-
tion arm, and early day-care attendance. Combined OR and 95% CI were derived from cohort-speciﬁc OR and 95% CI using a random eﬀects model. Note:
BAMSE, Children, Allergy, Milieu, Stockholm, Epidemiology; GINIplus, German Infant Nutritional Intervention; LISA, Inﬂuences of Lifestyle-Related
Factors on the Immune System and the Development of Allergies in Childhood; MAS, Multicentre Allergy Study; PIAMA, Prevention and Incidence of
Asthma and Mite Allergy.
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For asthma and rhinoconjunctivitis, the diﬀerences between
crude and adjusted eﬀect estimates were generally small (Figures
2 and 3), and slightly reduced but comparable results were
obtained from one-stage IPD-MA (see Table S5).
Tobacco Smoke Exposure and Phenotypes of Asthma
and Rhinoconjunctivitis
Associations between maternal smoking during pregnancy and
early transient, persistent, and adolescent-onset phenotypes are
presented in Figure 4. Compared with children who were unex-
posed during pregnancy, children with any exposure to maternal
smoking during pregnancy were more likely to have early tran-
sient asthma [OR=1:71 (95% CI: 1.21, 2.41)], and a nonsigniﬁ-
cantly increased odds ratio was observed for persistent asthma
[OR=1:22 (95% CI: 0.87, 1.71)]. Maternal smoking during preg-
nancy was also associated with persistent rhinoconjunctivitis
[OR=1:77 (95% CI: 1.20, 2.59)]. After additional adjustment for
SHS exposure throughout childhood, associations remained simi-
lar; however, the association with persistent rhinoconjunctivitis
Figure 2. (Continued.)
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was no longer statistically signiﬁcant [OR=1:79 (95% CI:
0.92, 3.48)]. In dose–response analyses, children exposed to
≥10 cigarettes=day during pregnancy had signiﬁcantly increased
odds of early transient and persistent asthma as well as
persistent rhinoconjunctivitis (Table 2). These results persisted
after additional adjustment for SHS exposure through child-
hood. Maternal smoking during pregnancy was not associated
with increased odds of adolescent-onset asthma [OR=0:77
Figure 3. Associations between maternal smoking during pregnancy (N =9,016) or any secondhand smoke (SHS) during infancy (N =7,932) and prevalence
of rhinoconjunctivitis up to 14 y of age in ﬁve European birth cohorts. Cohort-speciﬁc odds ratios (ORs) and 95% conﬁdence intervals (CIs) were obtained by
generalized estimating equation models. Adjusted for sex, parental education level, parental allergy, older siblings, breastfeeding, study center, intervention
arm, and early day-care attendance. Combined OR and 95% CI were derived from cohort-speciﬁc OR and 95% CI using a random eﬀects model. Note:
BAMSE, Children, Allergy, Milieu, Stockholm, Epidemiology; GINIplus, German Infant Nutritional Intervention; LISA, Inﬂuences of Lifestyle-Related
Factors on the Immune System and the Development of Allergies in Childhood; MAS, Multicentre Allergy Study; PIAMA, Prevention and Incidence of
Asthma and Mite Allergy.
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(95% CI: 0.52, 1.13)] or rhinoconjunctivitis [OR=0:98 (95%
CI: 0.78, 1.24)], and there were no evident dose–response
relationships.
Analyses of SHS exposure during infancy and phenotypes
of asthma and rhinoconjunctivitis showed no signiﬁcant associ-
ations (see Figure S3), and there were no apparent dose–
response relationships for any of the outcomes studied (see
Table S6).
We examined whether exposure to SHS during diﬀerent peri-
ods of childhood (infancy, 1–2, 4–6, 8–10, or 14–16 y of age) was
associated with adolescent-onset asthma and rhinoconjunctivitis,
but after adjustment for maternal smoking during pregnancy, no
signiﬁcant associations were apparent (Figure 5).
Sensitivity Analyses
Because the BAMSE cohort had the highest weight in the meta-
analyses, we performed a sensitivity analysis excluding this
cohort from the analyses. Following this exclusion, the point
estimate of the overall association between maternal smoking
Figure 3. (Continued.)
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during pregnancy and prevalent asthma up to adolescence
remained comparable [OR=1:14 (95% CI: 0.85, 1.53)].
We also performed analyses of the associations with tobacco
smoke exposure during pregnancy and during infancy stratiﬁed
by parental allergy. Associations of maternal smoking during
pregnancy with asthma and rhinoconjunctivitis appeared slightly
stronger among children without allergic parents than among
those with allergic parents, but interactions were not statistically
signiﬁcant: for asthma, OR=1:12 (95% CI: 0.88, 1.42) and
OR=1:03 (95% CI: 0.80, 1.35), respectively (interaction p=
0:55); for rhinoconjunctivitis OR=1:16 (95% CI: 0.93, 1.45) and
OR=1:07 (95% CI: 0.87, 1.31), respectively (interaction p=
0:61) (see Table S7). Associations between SHS during infancy
and both outcomes were positive among children without paren-
tal allergy and null among children with parental allergy, but
interactions were not statistically signiﬁcant (interaction p=0:30
and 0.12 for asthma and rhinoconjunctivitis, respectively) (see
Table S8).
Additionally, we performed analyses stratiﬁed by sex. Maternal
smoking and SHS during infancy were positively associated
with asthma in males but not in females (interaction
p-values = 0:47 and 0:34, respectively), but ORs for rhinoconjuncti-
vitis were similar for males and females for both exposures (interac-
tion p-values = 0:87 and 0:94, respectively) (see Tables S9 and
S10).
To assess the impact of the inclusion of preterm infants in the
BAMSE and PIAMA cohorts, we repeated analyses excluding
preterm infants (see Table S11). The results remained largely
unchanged.
In analyses of comorbidity of asthma and rhinoconjunctivitis,
we observed no clear associations for asthma only, rhinoconjunc-
tivitis only, or concurrent asthma and rhinoconjunctivitis in rela-
tion to exposure to maternal smoking during pregnancy or SHS
exposure during infancy (see Figures S4 and S5). We also con-
ducted analyses of diﬀerent windows of exposure: speciﬁcally,
maternal smoking during pregnancy only, parental smoking dur-
ing infancy only, and exposure to both in relation to asthma and
rhinoconjunctivitis (see Figure S6). We found evidence suggest-
ing that maternal smoking during pregnancy alone was associated
with asthma up to adolescence [OR=1:44 (95% CI: 1.10, 1.87)],
but no signiﬁcant associations were observed for rhinoconjuncti-
vitis. Lastly, we examined associations for any tobacco smoke
exposure during infancy or pregnancy compared with never-
smoker mothers (deﬁned as mothers who did not smoke during
pregnancy and during infancy), but the results were quite similar
(see Figure S7).
Discussion
Based on data from ﬁve European birth cohorts, exposure to
tobacco smoking during fetal life or infancy appears to increase
the odds of asthma up to 14–16 y of age, speciﬁcally early tran-
sient asthma. High exposure to cigarette smoking, ≥10 cigarettes=
day during pregnancy, was associated with persistent asthma and
persistent rhinoconjunctivitis. In contrast, there were no associa-
tions between tobacco smoke exposure (in utero, during infancy,
or later childhood) and the onset of asthma or rhinoconjunctivitis
in adolescence.
Our ﬁnding of an association between fetal and early post-
natal tobacco smoke exposure and asthma is in line with the cur-
rent literature in young children (Mitchell et al. 2012; Neuman
et al. 2012). Prospective studies and systematic reviews have also
found associations for maternal smoking during pregnancy and
childhood asthma (Burke et al. 2012; Silvestri et al. 2015), but
few studies have followed children into adolescence. Congruent
with our results, an Australian cohort showed an association
between maternal smoking during pregnancy and the risk of cur-
rent asthma at 14 y of age (Hollams et al. 2014). Additionally,
BAMSE, MAS, and PIAMA independently reported excess risk
of asthma up to adolescence in children exposed to SHS during
intrauterine life (Grabenhenrich et al. 2014; Milanzi et al. 2017;
Thacher et al. 2014). However, combining multiple cohorts pro-
vided power to adequately assess the timing of onset, progres-
sion, and persistence through distinct phenotypes. To our
knowledge, this is the ﬁrst study to investigate the eﬀects of
tobacco smoke exposure and phenotypes of asthma and rhinocon-
junctivitis development in children up to adolescence. Moreover,
SHS exposure in infancy or childhood was not associated with
onset of asthma in adolescence, and this ﬁnding is in line with
those of the few other studies that assessed adolescent-onset
asthma (Genuneit et al. 2006; Gilliland et al. 2006). Taken to-
gether, these results suggest that tobacco smoke exposure during
pregnancy primarily increases the risk of early-childhood asthma
and that high exposure may increase the risk of persistent asthma.
The evidence for an association between tobacco smoke
exposure and rhinoconjunctivitis up to adolescence is mixed
(Grabenhenrich et al. 2015; Mitchell et al. 2012; Thacher et al.
2014). We observed no statistically signiﬁcant association between
tobacco smoke exposure and prevalent rhinoconjuncti-vitis during
childhood and adolescence, but a statistically signiﬁcant dose–
response relationship appeared for persistent rhinoconjunctivitis in
Figure 4. Maternal smoking during pregnancy and the development of early
transient, persistent, and adolescent-onset disease phenotypes (asthmaN =7,210
and rhinoconjunctivitisN =6,991). Odds ratios (ORs) and 95% conﬁdence inter-
vals (CIs) were obtained by logistic regression and were adjusted for sex, paren-
tal education, parental allergy, secondhand smoke (SHS) during infancy, older
siblings, breastfeeding, study center, intervention arm, and early day-care
attendance.
Environmental Health Perspectives 047005-9
relation to the number of cigarettes smoked by the mother during
pregnancy. Previous studies have provided mixed results ranging
from reduced to excess risks in pediatric populations (Civelek et al.
2010; Magnusson et al. 2005; Mitchell et al. 2012). Independent
analyses in theBAMSEbirth cohort indicated that the risk of rhinitis
associated with tobacco smoke exposure was mainly conﬁned to
preschool-age children (Thacher et al. 2014).
Suggested mechanisms of how tobacco smoke inﬂuences the
development of asthma include increased airway responsiveness
and impaired immune response to viral pathogens (Macaubas
et al. 2003). Exposure to maternal smoking during pregnancy has
been shown to cause persistent epigenetic modiﬁcations,
particularly in enhancer regions regulating the activity of genes
involved in airway inﬂammatory processes, thus contributing to
the development of asthma symptoms among young children
(Bauer et al. 2016; Joubert et al. 2016). These symptoms may
persist into adolescence, particularly in highly exposed individu-
als. Furthermore, it is possible that altered lung growth and air-
way remodeling could contribute to persistent asthma among
subjects heavily exposed to maternal smoking during pregnancy.
The underlying mechanisms by which exposure to tobacco
smoke may aﬀect the development of rhinoconjunctivitis are
unclear. Studies indicate that maternal smoking during pregnancy
alters the adaptive and innate immune systems of newborns and
is associated with nasal obstruction, modiﬁcations in mucociliary
clearance in the airways, and modiﬁcations of the number and
function of T lymphocytes (Noakes et al. 2003).
Strengths of this study include the use of several European
birth cohorts, resulting in a large sample size and in harmonized
deﬁnitions of exposure and outcomes. The prospective cohort
design and long-term follow-up into adolescence are particularly
well suited to study the eﬀects of maternal smoking during preg-
nancy and SHS during infancy on outcomes in adolescence. A
large sample size facilitated robust analyses investigating early
transient, persistent, and adolescent-onset phenotypes as well as
the assessment of dose–response eﬀects.
Misclassiﬁcation of exposure or outcome is generally unavoid-
able in epidemiologic studies. With regard to maternal smoking
during pregnancy, all cohorts assessed this information shortly af-
ter birth; therefore, diﬀerential misclassiﬁcation of exposure is
reduced. The potential exists for parents to underreport smoking
habits because of social stigma. Validation studies have reported
agreement between questionnaire-reported tobacco smoking and
cord blood, plasma, or urinary cotinine levels in some studies
(Bauer et al. 2016; Brunekreef et al. 2000; Carlsten et al. 2012;
Gehring et al. 2006) but not in all (Britton et al. 2004). If underre-
porting is present in the included cohorts, our ﬁndings are likely to
underestimate the true association.
Outcome misclassiﬁcation is also a potential concern because
parents may not correctly recall symptoms or medical diagnoses.
We observed minor regional diﬀerences in asthma prevalence,
which may reﬂect diﬀering diagnostic criteria because doctor-
diagnosed asthma was one of three criteria used to deﬁne asthma.
The somewhat lower prevalence of asthma in the German cohorts
Figure 5. Secondhand smoke (SHS) exposure in childhood in relation to ad-
olescent-onset asthma and rhinoconjunctivitis. Odds ratios (ORs) and 95%
conﬁdence intervals (CIs) were obtained by logistic regression and were
adjusted for sex, parental education, parental allergy, older siblings, breast-
feeding, study center, intervention arm, day-care attendance, and maternal
smoking during pregnancy.
Table 2. The development of early-onset and persistent phenotypes of asthma and rhinoconjunctivitis in relation to intensity of maternal smoking during
pregnancy
Exposure
Maternal smoking during pregnancy
Na na Crude OR (95% CI) Adjusted OR (95% CI)b
Early transient asthma
No smoking 6,172 193 Reference Reference
Total of 1–9 cigarettes/day 446 20 1.39 (0.88, 2.17) 1.53 (1.16, 2.02)
Total of ≥10 cigarettes/day 294 26 2.54 (1.68, 3.85) 2.07 (1.60, 2.68)
Persistent asthma
No smoking 6,172 253 Reference Reference
Total of 1–9 cigarettes/day 446 19 1.08 (0.70, 1.67) 1.03 (0.78, 1.37)
Total of ≥10 cigarettes/day 294 26 2.25 (1.54, 3.29) 1.66 (1.29, 2.15)
Early transient rhinoconjunctivitis
No smoking 5,489 85 Reference Reference
Total of 1–9 cigarettes/day 401 5 0.92 (0.43, 2.00) 0.74 (0.44, 1.26)
Total of ≥10 cigarettes/day 283 10 2.27 (1.24, 4.18) 1.94 (1.30, 2.90)
Persistent rhinoconjunctivitis
No smoking 5,489 164 Reference Reference
Total of 1–9 cigarettes/day 401 21 1.72 (1.14, 2.59) 1.75 (1.32, 2.31)
Total of ≥10 cigarettes/day 283 13 1.83 (1.14, 2.93) 1.55 (1.09, 2.20)
Note: CI, confidence interval; OR, odds ratio.
aN = total number of exposed children; n = number of exposed cases.
bORs and 95% CIs obtained from multinomial logistic regression analyses adjusted for sex, parental education level, parental allergy, older siblings, breastfeeding, study center, inter-
vention arm, and early day-care attendance.
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(GINIplus, LISAplus, and MAS) might be explained by diﬀerent
diagnostic conventions between countries (Gehring et al. 2015).
Respiratory symptoms are more common among children exposed
to parental smoking, and studies indicate that smoking parents
may underreport symptoms of wheeze or underutilize health care
for mild respiratory symptoms in their children (Crombie et al.
2001). This underreporting could contribute to an underestimation
of the true eﬀect. Additionally, exposure to SHS later in childhood
is not always independent of symptoms in the child because some
parents may quit smoking if their child is diagnosed with asthma
(Wijga et al. 2017).
Nonrandom retention of study participants may have inﬂu-
enced our ﬁndings and should be acknowledged. We cannot rule
out some selection bias due to missing data. Additionally, vary-
ing degrees of missing data across cohorts and exposure windows
could also have biased our results. Nevertheless, cohort retention
was good, and the baseline characteristics of our study population
did not diﬀer greatly from those of the initial cohorts. Thus, it is
unlikely that our ﬁndings are explained by selection bias or by
missing data.
In MAS, atopic parents were overrepresented by design.
Therefore, we adjusted our analyses for parental allergy, and our
results comparing crude and adjusted models were similar.
Additionally, cohort-speciﬁc estimates in MAS tended to be
larger for asthma than those in the other cohorts. This diﬀerence
may be due to the recruitment period because MAS was estab-
lished some years before the other cohorts and had the highest
smoking rates.
It is possible that the I2 is not sensitive enough to capture het-
erogeneity between studies if the number of studies is small, and
all but one study show similar associations. Similarly, when ana-
lyzing pooled data, we included a term for cohort; however, this
may not fully account for unmeasured eﬀects in each cohort and
should be acknowledged (Rosa et al. 2017). Therefore, we also
adjusted for important demographic variables such as education
level to capture diﬀerences in other social factors between the
cohorts. Nevertheless, these ﬁve cohorts are from high-income
European countries and are likely to be similar in many aspects.
Conclusion
Taken together, our ﬁndings strengthen and extend results from
previous studies reporting that any form of tobacco smoke expo-
sure during fetal life or infancy increases the risk of asthma in
childhood and adolescence, particularly the risk of early transient
asthma. The risks of persistent asthma and persistent rhinocon-
junctivitis were increased in highly exposed subjects. We found
no evidence of an association between tobacco smoke exposure
during fetal life, infancy, or any time during childhood and the
onset of asthma or rhinoconjunctivitis in adolescence.
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